AstraZeneca’s Ultomiris Nears EU Green Light For NMOSD
After Positive CHMP Opinion
The UK major’s long-acting C5 inhibitor is nearing EU approval for the debilitating rare disease as the company gears up for emerging competition and loss of exclusivity for its older drug Soliris.
You may also be interested in...
Samsung Bioepis has seen its SB12 proposed eculizumab biosimilar rival to Soliris endorsed by the EMA’s CHMP. At the same time, three generics also received positive CHMP opinions.
The UK major believes it can maintain growth trajectory through novel combinations regimens and pipeline diversification despite the anticipated expiration of several blockbuster drug patents over the next decade.
Roche is looking to challenge AstraZeneca's dominance in PNH with its subcutaneously administered once-a-month treatment but could struggle to rival the company's and Novartis’s oral therapy.